Summit Therapeutics Inc. Investment Income, Interest
Summit Therapeutics Inc. (SMMT) reported Investment Income, Interest of $1.76 million for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-11.
Discontinued › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2023-05-11
- Summit Therapeutics Inc. investment income, interest for the quarter ending 2023-03-31 was $1.76M.
- Summit Therapeutics Inc. investment income, interest for the quarter ending 2022-03-31 was $0.00.
- Summit Therapeutics Inc. investment income, interest for fiscal 2022 was $1.51M.
- Summit Therapeutics Inc. investment income, interest for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- Summit Therapeutics Inc. investment income, interest for fiscal 2020 was $4.00K.
- Summit Therapeutics Inc. investment income, interest for fiscal 2019 was $5.00K.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 11 month | Investment Income, Interest 12 month |
|---|---|---|---|
| 2023-03-31 | $1.76M 10-Q · filed 2023-05-11 | ||
| 2022-12-31 | $1.51M 10-K · filed 2023-03-09 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-11 | ||
| 2021-12-31 | $0.00 10-K · filed 2023-03-09 | ||
| 2020-12-31 | $4.00K 10-K/A · filed 2022-12-21 | ||
| 2019-12-31 | $5.00K 10-K · filed 2021-03-31 | ||
| 2019-01-31 | $5.00K 10-K · filed 2021-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |